ABSTRACT
The present invention discloses a method of gene expression profiling to identify genomic signatures linked to survival specific for a disease and a kit that can be used for performing such a method. Also disclosed herein is the use of such a method in classifying the disease into subsets, predicting clinical outcome and survival of an individual, selecting treatment for an individual suffering from a disease, predicting post-relapse risk and survival of an individual, correlating molecular classification of a disease with genomic signature defining the risk group or a combination thereof.
CLAIMS
1. A method of gene expression profiling to identify genomic signatures linked to a prognosis of survival in a subject with symptomatic multiple myeloma or multiple myeloma, comprising: determining the expression levels of genes consisting of KIF14, SLC19A1, CKS1B, YWHAZ, MPHOSPH1, TMPO, NADK, LARS2, TBRG4, AIM2, ASPM, AHCYL1, CTBS, MCLC, LTBP1 and genes detectable with nucleic acids having the Affymetrix reference numbers 242488_at and 1557277_a_at on a U133Plus2.0 Affymetrix microarray, in a nucleic acid sample from plasma cells isolated from the subject; and determining the presence of abnormal expression levels, thereby prognosing the subject.